Vascular Disease Pipeline
Pairing the Orion GENESYS™ delivery platform with novel RNA approaches.
Key Features of our Restenosis Asset
Targeted Delivery
Our LNP targets the exposed subendothelial matrix of injured vascular tissues, ensuring precise delivery to areas affected by atherosclerosis and surgical interventions
siRNA
Specifically designed to inhibit enzymes involved in vascular smooth muscle proliferation and intimal hyperplasia, key factors in the development of restenosis
Versatile Delivery Options
Engineered for both intravenous and localized delivery methods to adapt to patient needs and surgical contexts
NSF Phase I STTR Support
Backed by the National Science Foundation’s commitment to advancing cutting-edge medical technologies